Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODM-201 maintenance therapy in non-progressive metastatic castration-resistant prostate cancer
2016-003996-23Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of darolutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Radiographic progression-free survival. Started Nov 2018; status: terminated.
02
Drugs
darolutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-003996-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003996-23.